<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911021-0082</DOCNO><DOCID>911021-0082.</DOCID><HL>   Technology:   Repligen, Merck Conduct   Study on AIDS Treatment</HL><DATE>10/21/91</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   MRK RGEN</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>DRUG MANUFACTURERS (DRG)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><RE>MASSACHUSETTS (MA)NEW JERSEY (NJ)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   CAMBRIDGE, Mass. -- Repligen Corp. said that along withMerck andamp; Co. it has conducted two animal studies &quot;indicatingit may be feasible to develop an anti-infective&quot; against AIDSinfections in humans.   Repligen said that in the latest study, a chimpanzee wasinjected with infectious doses of the virus that causesacquired immune deficiency syndrome, then later injected witha monoclonal antibody that targets a part of the virus calledthe V3 loop. The animal has remained free of AIDS infectionsince March 1991 when the test was begun, Repligen said.</LP><TEXT>   In an earlier study, researchers first injected themonoclonal antibody into a chimpanzee, then &quot;challenged&quot; theanimal with an infectious dose of the AIDS virus, Repligensaid. The study indicated the antibody has potential toprevent AIDS infections before exposure to the virus, thecompany added.   Both studies are being presented by a Merck researcher atan AIDS conference in Marco Island, Fla., Repligen said.Human trials of AIDS vaccines based on the work are &quot;at leasta year away,&quot; said a Repligen spokesman.</TEXT></DOC>